{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T21:20:08Z","timestamp":1790889608895,"version":"4.1.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,23]],"date-time":"2025-08-23T00:00:00Z","timestamp":1755907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,8,23]],"date-time":"2025-08-23T00:00:00Z","timestamp":1755907200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100007847","name":"Natural Science Foundation of Jilin Province","doi-asserted-by":"publisher","award":["YDZJ202201ZYTS092"],"award-info":[{"award-number":["YDZJ202201ZYTS092"]}],"id":[{"id":"10.13039\/100007847","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-15360-7","type":"journal-article","created":{"date-parts":[[2025,8,23]],"date-time":"2025-08-23T02:17:08Z","timestamp":1755915428000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The hidden costs of PEG-rhG-CSF in autologous stem cell transplantation for newly diagnosed multiple myeloma"],"prefix":"10.1038","volume":"15","author":[{"given":"Ruiqi","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenxing","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Cong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuansong","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9159-2747","authenticated-orcid":false,"given":"Wenlong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,23]]},"reference":[{"key":"15360_CR1","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/s41408-022-00645-1","volume":"12","author":"AH Bazarbachi","year":"2022","unstructured":"Bazarbachi, A. H. et al. Induction therapy prior to autologous stem cell transplantation (ASCT) in newly diagnosed multiple myeloma: An update. Blood Cancer J. 12, 47. https:\/\/doi.org\/10.1038\/s41408-022-00645-1 (2022).","journal-title":"Blood Cancer J."},{"key":"15360_CR2","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1111\/j.1600-0609.2005.00605.x","volume":"76","author":"E Jantunen","year":"2006","unstructured":"Jantunen, E. et al. Early treatment-related mortality in adult autologous stem cell transplant recipients: A nation-wide survey of 1482 transplanted patients. Eur. J. Haematol. 76, 245\u2013250. https:\/\/doi.org\/10.1111\/j.1600-0609.2005.00605.x (2006).","journal-title":"Eur. J. Haematol."},{"key":"15360_CR3","doi-asserted-by":"publisher","first-page":"34","DOI":"10.5001\/omj.2019.06","volume":"34","author":"MN Hassan","year":"2019","unstructured":"Hassan, M. N. et al. Autologous peripheral blood stem cell transplantation among lymphoproliferative disease patients: Factors influencing engraftment. Oman Med. J. 34, 34\u201343. https:\/\/doi.org\/10.5001\/omj.2019.06 (2019).","journal-title":"Oman Med. J."},{"key":"15360_CR4","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.3906\/sag-2001-173","volume":"50","author":"E Alada\u011f Karakulak","year":"2020","unstructured":"Alada\u011f Karakulak, E. et al. CD34+ hematopoietic progenitor cell dose as a predictor of engraftment and survival in multiple myeloma patients undergoing autologous stem cell transplantation. Turk. J. Med. Sci. 50, 1851\u20131856. https:\/\/doi.org\/10.3906\/sag-2001-173 (2020).","journal-title":"Turk. J. Med. Sci."},{"key":"15360_CR5","doi-asserted-by":"publisher","first-page":"103809","DOI":"10.1016\/j.transci.2023.103809","volume":"62","author":"I Serin","year":"2023","unstructured":"Serin, I. et al. Plerixafor in autologous stem cell transplantation: Does it affect engraftment kinetics?. Transfus. Apher. Sci. Off. J. World Apher. Assoc. Off. J. Eur. Soc. Haemapher. 62, 103809. https:\/\/doi.org\/10.1016\/j.transci.2023.103809 (2023).","journal-title":"Transfus. Apher. Sci. Off. J. World Apher. Assoc. Off. J. Eur. Soc. Haemapher."},{"key":"15360_CR6","doi-asserted-by":"publisher","first-page":"2709","DOI":"10.1111\/trf.13233","volume":"55","author":"T Pham","year":"2015","unstructured":"Pham, T. et al. Comparison of biosimilar filgrastim with originator filgrastim for peripheral blood stem cell mobilization and engraftment in patients with multiple myeloma undergoing autologous stem cell transplantation. Transfusion 55, 2709\u20132713. https:\/\/doi.org\/10.1111\/trf.13233 (2015).","journal-title":"Transfusion"},{"key":"15360_CR7","doi-asserted-by":"publisher","first-page":"478","DOI":"10.2450\/2015.0198-14","volume":"13","author":"S Bassi","year":"2015","unstructured":"Bassi, S. et al. Safety and efficacy of granulocyte colony-stimulating factor biosimilars in engraftment after autologous stem cell transplantation for haematological malignancies: A 4-year, single institute experience with different conditioning regimens. Blood Transfus. Trasfusione del sangue 13, 478\u2013483. https:\/\/doi.org\/10.2450\/2015.0198-14 (2015).","journal-title":"Blood Transfus. Trasfusione del sangue"},{"key":"15360_CR8","doi-asserted-by":"publisher","first-page":"103809","DOI":"10.1016\/j.transci.2023.103809","volume":"62","author":"I Serin","year":"2023","unstructured":"Serin, I. et al. Plerixafor in autologous stem cell transplantation: Does it affect engraftment kinetics?. Transfus. Apher. Sci. 62, 103809. https:\/\/doi.org\/10.1016\/j.transci.2023.103809 (2023).","journal-title":"Transfus. Apher. Sci."},{"key":"15360_CR9","doi-asserted-by":"publisher","first-page":"3439","DOI":"10.3390\/cancers13143439","volume":"13","author":"EM Klein","year":"2021","unstructured":"Klein, E. M. et al. Antibiotic prophylaxis or granulocyte-colony stimulating factor support in multiple myeloma patients undergoing autologous stem cell transplantation. Cancers 13, 3439. https:\/\/doi.org\/10.3390\/cancers13143439 (2021).","journal-title":"Cancers"},{"key":"15360_CR10","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1080\/10428194.2020.1827244","volume":"62","author":"V Singh","year":"2021","unstructured":"Singh, V. et al. G-CSF use post peripheral blood stem cell transplant is associated with faster neutrophil engraftment, shorter hospital stay and increased incidence of chronic GVHD. Leuk. Lymphoma 62, 446\u2013453. https:\/\/doi.org\/10.1080\/10428194.2020.1827244 (2021).","journal-title":"Leuk. Lymphoma"},{"key":"15360_CR11","doi-asserted-by":"publisher","first-page":"2882","DOI":"10.1016\/j.transproceed.2014.09.070","volume":"46","author":"M Cioch","year":"2014","unstructured":"Cioch, M. et al. Biosimilar granulocyte colony-stimulating factor is effective in reducing the duration of neutropenia after autologous peripheral blood stem cell transplantation. Transpl. Proc. 46, 2882\u20132884. https:\/\/doi.org\/10.1016\/j.transproceed.2014.09.070 (2014).","journal-title":"Transpl. Proc."},{"key":"15360_CR12","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.bbmt.2017.10.026","volume":"24","author":"AD Singh","year":"2018","unstructured":"Singh, A. D. et al. Granulocyte colony-stimulating factor use after autologous peripheral blood stem cell transplantation: Comparison of two practices. Biol. Blood Marrow Transplant. J. Am. Soc. Blood Marrow Transplant. 24, 288\u2013293. https:\/\/doi.org\/10.1016\/j.bbmt.2017.10.026 (2018).","journal-title":"Biol. Blood Marrow Transplant. J. Am. Soc. Blood Marrow Transplant."},{"key":"15360_CR13","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1097\/00001813-200304000-00002","volume":"14","author":"G Molineux","year":"2003","unstructured":"Molineux, G. Pegfilgrastim: Using pegylation technology to improve neutropenia support in cancer patients. Anticancer Drugs 14, 259\u2013264. https:\/\/doi.org\/10.1097\/00001813-200304000-00002 (2003).","journal-title":"Anticancer Drugs"},{"key":"15360_CR14","doi-asserted-by":"publisher","first-page":"5075","DOI":"10.1007\/s00520-021-06045-8","volume":"29","author":"L Roder","year":"2021","unstructured":"Roder, L., Konrardy, K., Grauer, D. & Hoffmann, M. Effects of filgrastim versus pegfilgrastim on outcomes of DA-R-EPOCH for non-Hodgkin\u2019s lymphoma. Support. Care Cancer Off. J. Multinatl. Assoc. Support. Care Cancer 29, 5075\u20135082. https:\/\/doi.org\/10.1007\/s00520-021-06045-8 (2021).","journal-title":"Support. Care Cancer Off. J. Multinatl. Assoc. Support. Care Cancer"},{"key":"15360_CR15","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1186\/s12913-022-08933-z","volume":"22","author":"GT Gebremariam","year":"2022","unstructured":"Gebremariam, G. T., Fentie, A. M., Beyene, K., Sander, B. & Gebretekle, G. B. Cost-effectiveness of pegfilgrastim versus filgrastim for prevention of chemotherapy-induced febrile neutropenia in patients with lymphoma: A systematic review. BMC Health Serv. Res. 22, 1600. https:\/\/doi.org\/10.1186\/s12913-022-08933-z (2022).","journal-title":"BMC Health Serv. Res."},{"key":"15360_CR16","doi-asserted-by":"publisher","first-page":"2172292","DOI":"10.1080\/16078454.2023.2172292","volume":"28","author":"X Zhu","year":"2023","unstructured":"Zhu, X. et al. Pegfilgrastim on febrile neutropenia in pediatric and adolescent cancer patients: A systematic review and meta-analysis. Hematology 28, 2172292. https:\/\/doi.org\/10.1080\/16078454.2023.2172292 (2023).","journal-title":"Hematology"},{"key":"15360_CR17","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11237053","author":"H Gwak","year":"2022","unstructured":"Gwak, H. et al. COVID-19 prevention guidance and the incidence of febrile neutropenia in patients with breast cancer receiving TAC chemotherapy with prophylactic pegfilgrastim. J. Clin. Med. https:\/\/doi.org\/10.3390\/jcm11237053 (2022).","journal-title":"J. Clin. Med."},{"key":"15360_CR18","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.21873\/anticanres.16393","volume":"43","author":"T Kurogochi","year":"2023","unstructured":"Kurogochi, T. et al. Efficacy and cost-effectiveness of pegfilgrastim for preventing febrile neutropenia during docetaxel, cisplatin, and 5-fluorouracil therapy for esophageal cancer. Anticancer Res. 43, 2293\u20132298. https:\/\/doi.org\/10.21873\/anticanres.16393 (2023).","journal-title":"Anticancer Res."},{"key":"15360_CR19","doi-asserted-by":"publisher","first-page":"766","DOI":"10.4143\/crt.2022.987","volume":"55","author":"YW Moon","year":"2023","unstructured":"Moon, Y. W. et al. Eflapegrastim versus pegfilgrastim for chemotherapy-induced neutropenia in Korean and Asian patients with early breast cancer: Results from the two phase iii advance and recover studies. Cancer Res. Treat. 55, 766\u2013777. https:\/\/doi.org\/10.4143\/crt.2022.987 (2023).","journal-title":"Cancer Res. Treat."},{"key":"15360_CR20","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1007\/s00277-023-05228-z","volume":"102","author":"M Martino","year":"2023","unstructured":"Martino, M. et al. Effectiveness of biosimilar pegfilgrastim in patients with multiple myeloma after high-dose melphalan and autologous stem cell transplantation. Ann. Hematol. 102, 1915\u20131925. https:\/\/doi.org\/10.1007\/s00277-023-05228-z (2023).","journal-title":"Ann. Hematol."},{"key":"15360_CR21","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1038\/s41409-018-0264-8","volume":"54","author":"WI Gonsalves","year":"2019","unstructured":"Gonsalves, W. I. et al. Utilization of hematopoietic stem cell transplantation for the treatment of multiple myeloma: A mayo stratification of myeloma and risk-adapted therapy (mSMART) consensus statement. Bone Marrow Transplant. 54, 353\u2013367. https:\/\/doi.org\/10.1038\/s41409-018-0264-8 (2019).","journal-title":"Bone Marrow Transplant."},{"key":"15360_CR22","doi-asserted-by":"publisher","first-page":"3412","DOI":"10.1200\/jco.2005.04.242","volume":"23","author":"PR Greipp","year":"2005","unstructured":"Greipp, P. R. et al. International staging system for multiple myeloma. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 23, 3412\u20133420. https:\/\/doi.org\/10.1200\/jco.2005.04.242 (2005).","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"15360_CR23","doi-asserted-by":"publisher","first-page":"2863","DOI":"10.1200\/jco.2015.61.2267","volume":"33","author":"A Palumbo","year":"2015","unstructured":"Palumbo, A. et al. Revised international staging system for multiple myeloma: A report from international myeloma working group. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 33, 2863\u20132869. https:\/\/doi.org\/10.1200\/jco.2015.61.2267 (2015).","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"15360_CR24","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1038\/leu.2011.131","volume":"25","author":"F Cavallo","year":"2011","unstructured":"Cavallo, F. et al. Stem cell mobilization in patients with newly diagnosed multiple myeloma after lenalidomide induction therapy. Leukemia 25, 1627\u20131631. https:\/\/doi.org\/10.1038\/leu.2011.131 (2011).","journal-title":"Leukemia"},{"key":"15360_CR25","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1136\/jcp.52.5.376","volume":"52","author":"PC Huijgens","year":"1999","unstructured":"Huijgens, P. C. et al. Fluconazole versus itraconazole for the prevention of fungal infections in haemato-oncology. J. Clin. Pathol. 52, 376\u2013380. https:\/\/doi.org\/10.1136\/jcp.52.5.376 (1999).","journal-title":"J. Clin. Pathol."},{"key":"15360_CR26","doi-asserted-by":"publisher","first-page":"e298","DOI":"10.1016\/j.bbmt.2019.07.018","volume":"25","author":"K Gkirkas","year":"2019","unstructured":"Gkirkas, K. et al. Low-dose cotrimoxazole administered in hematopoietic stem cell transplant recipients as prophylaxis for Pneumocystis jirovecii pneumonia is effective in prevention of infection due to nocardia. Biol. Blood Marrow Transplant. J. Am. Soc. Blood Marrow Transplant. 25, e298\u2013e299. https:\/\/doi.org\/10.1016\/j.bbmt.2019.07.018 (2019).","journal-title":"Biol. Blood Marrow Transplant. J. Am. Soc. Blood Marrow Transplant."},{"key":"15360_CR27","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1080\/16078454.2021.2003071","volume":"26","author":"X Wang","year":"2021","unstructured":"Wang, X., Ren, J., Liang, X. & He, P. Efficacy and cost of G-CSF derivatives for prophylaxis of febrile neutropenia in lymphoma and multiple myeloma patients underwent autologous hematopoietic stem cell transplantation. Hematology 26, 950\u2013955. https:\/\/doi.org\/10.1080\/16078454.2021.2003071 (2021).","journal-title":"Hematology"},{"key":"15360_CR28","doi-asserted-by":"publisher","first-page":"696.e691","DOI":"10.1016\/j.jtct.2023.08.021","volume":"29","author":"AJ Portuguese","year":"2023","unstructured":"Portuguese, A. J. et al. Revisiting the utility of granulocyte colony-stimulating factor post-autologous hematopoietic stem cell transplantation for outpatient-based transplantations. Transplant. Cell Ther. 29, 696.e691-696.e697. https:\/\/doi.org\/10.1016\/j.jtct.2023.08.021 (2023).","journal-title":"Transplant. Cell Ther."},{"key":"15360_CR29","doi-asserted-by":"publisher","first-page":"402","DOI":"10.21147\/j.issn.1000-9604.2017.05.04","volume":"29","author":"Y Qin","year":"2017","unstructured":"Qin, Y. et al. A phase I study of different doses and frequencies of pegylated recombinant human granulocyte-colony stimulating factor (PEG rhG-CSF) in patients with standard-dose chemotherapy-induced neutropenia. Chin. J. Cancer Res. 29, 402\u2013410. https:\/\/doi.org\/10.21147\/j.issn.1000-9604.2017.05.04 (2017).","journal-title":"Chin. J. Cancer Res."},{"key":"15360_CR30","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1080\/14653240600847241","volume":"8","author":"AC Zubair","year":"2006","unstructured":"Zubair, A. C. et al. CD34(+) CD38(\u2212) and CD34(+) HLA-DR(\u2212) cells in BM stem cell grafts correlate with short-term engraftment but have no influence on long-term hematopoietic reconstitution after autologous transplantation. Cytotherapy 8, 399\u2013407. https:\/\/doi.org\/10.1080\/14653240600847241 (2006).","journal-title":"Cytotherapy"},{"key":"15360_CR31","doi-asserted-by":"publisher","first-page":"4557","DOI":"10.1007\/s00277-024-05975-7","volume":"103","author":"SR Goldsmith","year":"2024","unstructured":"Goldsmith, S. R. et al. A phase Ib trial of isatuximab, bendamustine, and prednisone in relapsed\/refractory multiple myeloma. Ann. Hematol. 103, 4557\u20134565. https:\/\/doi.org\/10.1007\/s00277-024-05975-7 (2024).","journal-title":"Ann. Hematol."},{"key":"15360_CR32","doi-asserted-by":"publisher","first-page":"5085","DOI":"10.1007\/s00520-020-05603-w","volume":"28","author":"X Li","year":"2020","unstructured":"Li, X. et al. Is PEGylated G-CSF superior to G-CSF in patients with breast cancer receiving chemotherapy? A systematic review and meta-analysis. Support. Care Cancer Off. J. Multinatl. Assoc. Support. Care Cancer 28, 5085\u20135097. https:\/\/doi.org\/10.1007\/s00520-020-05603-w (2020).","journal-title":"Support. Care Cancer Off. J. Multinatl. Assoc. Support. Care Cancer"},{"key":"15360_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtocrr.2023.100569","volume":"4","author":"M Tachihara","year":"2023","unstructured":"Tachihara, M. et al. Docetaxel plus ramucirumab with primary prophylactic pegylated granulocyte-colony stimulating factor support for elderly patients with advanced NSCLC: A multicenter prospective single arm phase 2 trial: Dragon study (WJOG9416L). JTO Clin. Res. Rep. 4, 100569. https:\/\/doi.org\/10.1016\/j.jtocrr.2023.100569 (2023).","journal-title":"JTO Clin. Res. Rep."},{"key":"15360_CR34","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1007\/s10147-024-02504-4","volume":"29","author":"T Yoshinami","year":"2024","unstructured":"Yoshinami, T. et al. Comparison between a single dose of PEG G-CSF and multiple doses of non-PEG G-CSF: A systematic review and meta-analysis from clinical practice guidelines for the use of G-CSF 2022. Int. J. Clin. Oncol. 29, 681\u2013688. https:\/\/doi.org\/10.1007\/s10147-024-02504-4 (2024).","journal-title":"Int. J. Clin. Oncol."},{"key":"15360_CR35","doi-asserted-by":"publisher","first-page":"831","DOI":"10.3760\/cma.j.issn.0253-2727.2017.10.002","volume":"38","author":"F Yang","year":"2017","unstructured":"Yang, F. et al. [Comparative study on the efficacy and safety between pegfilgrastim (PEG-rhG-CSF) and recombinant human granulocyte colony-stimulating factor in promoting hematopoietic recovery after allogeneic hematopoietic stem cell transplantation after hematological malignancy]. Zhonghua xue ye xue za zhi Zhonghua xueyexue zazhi 38, 831\u2013836. https:\/\/doi.org\/10.3760\/cma.j.issn.0253-2727.2017.10.002 (2017).","journal-title":"Zhonghua xue ye xue za zhi Zhonghua xueyexue zazhi"},{"key":"15360_CR36","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1007\/s12288-023-01704-8","volume":"40","author":"S Li","year":"2024","unstructured":"Li, S. et al. The effectiveness and optimal timing of PEG-rhG-CSF after autologous peripheral blood stem cell transplantation: A multicenter experience. Indian J. Hematol. Blood Transfus. Off. J. Indian Soc. of Hematol. Blood Transfus. 40, 190\u2013195. https:\/\/doi.org\/10.1007\/s12288-023-01704-8 (2024).","journal-title":"Indian J. Hematol. Blood Transfus. Off. J. Indian Soc. of Hematol. Blood Transfus."},{"key":"15360_CR37","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1093\/annonc\/mdp576","volume":"21","author":"L Castagna","year":"2010","unstructured":"Castagna, L. et al. Pegfilgrastim versus filgrastim after high-dose chemotherapy and autologous peripheral blood stem cell support. Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. 21, 1482\u20131485. https:\/\/doi.org\/10.1093\/annonc\/mdp576 (2010).","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"15360_CR38","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/j.exphem.2005.11.013","volume":"34","author":"G Vanstraelen","year":"2006","unstructured":"Vanstraelen, G. et al. Pegfilgrastim compared with filgrastim after autologous hematopoietic peripheral blood stem cell transplantation. Exp. Hematol. 34, 382\u2013388. https:\/\/doi.org\/10.1016\/j.exphem.2005.11.013 (2006).","journal-title":"Exp. Hematol."},{"key":"15360_CR39","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1200\/jco.2004.06.102","volume":"22","author":"O Ringd\u00e9n","year":"2004","unstructured":"Ringd\u00e9n, O. et al. Treatment with granulocyte colony-stimulating factor after allogeneic bone marrow transplantation for acute leukemia increases the risk of graft-versus-host disease and death: A study from the acute leukemia working party of the European group for blood and marrow transplantation. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 22, 416\u2013423. https:\/\/doi.org\/10.1200\/jco.2004.06.102 (2004).","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"15360_CR40","doi-asserted-by":"publisher","first-page":"113624","DOI":"10.1016\/j.bcp.2019.113624","volume":"169","author":"Y Li","year":"2019","unstructured":"Li, Y. et al. G-CSF administration results in thrombocytopenia by inhibiting the differentiation of hematopoietic progenitors into megakaryocytes. Biochem. Pharmacol. 169, 113624. https:\/\/doi.org\/10.1016\/j.bcp.2019.113624 (2019).","journal-title":"Biochem. Pharmacol."},{"key":"15360_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.transci.2022.103482","volume":"61","author":"A Sar\u0131c\u0131","year":"2022","unstructured":"Sar\u0131c\u0131, A. et al. The effect of G-CSF used after allogeneic hematopoietic stem cell transplantation on engraftment times and platelet suspension replacement numbers. Transfus. Apher. Sci. Off. J. World Apher. Assoc. Off. J. Eur. Soc. Haemapher. 61, 103482. https:\/\/doi.org\/10.1016\/j.transci.2022.103482 (2022).","journal-title":"Transfus. Apher. Sci. Off. J. World Apher. Assoc. Off. J. Eur. Soc. Haemapher."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-15360-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-15360-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-15360-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,23]],"date-time":"2025-08-23T02:17:12Z","timestamp":1755915432000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-15360-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,23]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["15360"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-15360-7","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,23]]},"assertion":[{"value":"6 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"30992"}}